EVK Stock Analysis: Evonik Industries | XETRA

Specialty Chemicals | XETRA, Germany | Market Cap: 8.369m EUR | 12M Return: 14.5% | DE000EVNK013 | Charts, Fundamentals & Technical Analysis

Additives, Methionine, Silicas, Peroxide
Total Rating 46
Safety 69
Buy Signal 0.55
Specialty Chemicals
Industry Rotation: +14.2
Market Cap: 9.66B
Avg Turnover: 19.1M
Risk 3d forecast
Volatility21.2%
VaR 5th Pctl3.62%
VaR vs Median3.53%
Reward TTM
Sharpe Ratio0.50
Rel. Str. IBD64.3
Rel. Str. Peer Group52.6
Character TTM
Beta-0.018
Beta Downside-0.061
Hurst Exponent0.586
Drawdowns 3y
Max DD39.76%
CAGR/Max DD0.18
CAGR/Mean DD0.52
EPS (Earnings per Share) EPS (Earnings per Share) of EVK over the last years for every Quarter: "2021-06": 0.54, "2021-09": 0.58, "2021-12": 0.49, "2022-03": 0.76, "2022-06": 0.75, "2022-09": 0.54, "2022-12": 0.2, "2023-03": 0.25, "2023-06": 0.26, "2023-09": 0.41, "2023-12": -0.13, "2024-03": 0.42, "2024-06": 0.5, "2024-09": 0.58, "2024-12": 0.16, "2025-03": 0.59, "2025-06": 0.34, "2025-09": 0.27, "2025-12": 0.15, "2026-03": 0.34, "2026-06": 0.65,
EPS CAGR: 13.76%
EPS Trend: 47.9%
Last SUE: 1.37
Qual. Beats: 1
Revenue Revenue of EVK over the last years for every Quarter: 2021-06: 3636, 2021-09: 3871, 2021-12: 4090, 2022-03: 4498, 2022-06: 4772, 2022-09: 4878, 2022-12: 4340, 2023-03: 4005, 2023-06: 3886, 2023-09: 3771, 2023-12: 3605, 2024-03: 3796, 2024-06: 3930, 2024-09: 3832, 2024-12: 3599, 2025-03: 3777, 2025-06: 3499, 2025-09: 3391, 2025-12: 3403, 2026-03: 3427, 2026-06: 3893,
Rev. CAGR: -4.37%
Rev. Trend: -91.4%
Last SUE: 0.06
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

Confidence

Seasonality 11.6 years of data

Jan +0.4% 17
Feb +0.1% 19
Mar -1.7% 16
Apr +2.2% 19
May +1.0% 8
Jun -0.1% 7
Jul +1.9% 38
Aug -4.3% 20
Sep -3.0% 31
Oct +0.1% 2
Nov -4.0% 31
Dec +0.5% 2

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: EVK Evonik Industries

Evonik Industries AG is a German specialty chemicals company headquartered in Essen, founded in 1847. It operates globally across Asia-Pacific, Europe, the Middle East, Africa, and the Americas through three reporting segments: Advanced Technologies, Custom Solutions, and Infrastructure.

The Advanced Technologies segment supplies performance chemicals such as medical-grade polymers, hydrogen peroxide (used in semiconductor wafer cleaning and pulp/paper bleaching), specialty silicas and silanes for tires, electronics, and cosmetics, and the essential amino acids D-/L-methionine and lysine for animal feed. Evonik is one of the worlds largest producers of methionine, a key feed additive for poultry and swine, reflecting the companys deep position in life-sciences-oriented specialty chemistry rather than commodity chemicals.

The Custom Solutions segment focuses on functional additives for coatings, adhesives, sealants, polyurethane foams, and lubricants serving cosmetics, cleaning, and pharmaceutical end-markets. The Infrastructure segment supplies C4-based petrochemical intermediates, including butadiene, MTBE, butene-1, isononanol, and DINP, which feed into plastics, packaging, rubber, fuel production, and as plasticizers for the construction and automotive industries.

Headlines to Watch Out For
  • Methionine oversupply pressures animal nutrition segment margins
  • High European energy costs squeeze German production profitability
  • Construction slowdown weakens plasticizer and coatings additives demand
Piotroski VR-10 (Strict) 4.0
Net Income: 121.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA 2.07 > 1.0
NWC/Revenue: 13.29% < 20% (prev 11.74%; Δ 1.55% < -1%)
CFO/TA 0.09 > 3% & CFO 1.63b > Net Income 121.0m
Net Debt (4.94b) to EBITDA (2.11b): 2.34 < 3
Current Ratio: 1.50 > 1.5 & < 3
Outstanding Shares: last quarter (466.0m) vs 12m ago 0.97% < -2%
Gross Margin: 22.18% > 18% (prev 24.69%; Δ -2.51% > 0.5%)
Asset Turnover: 74.94% > 50% (prev 77.19%; Δ -2.25% > 0%)
Interest Coverage Ratio: 3.69 > 6 (EBIT TTM 796.0m / Interest Expense TTM 216.0m)
Altman Z'' 2.91
A: 0.10 (Total Current Assets 5.66b - Total Current Liabilities 3.78b) / Total Assets 18.6b
B: 0.37 (Retained Earnings 6.82b / Total Assets 18.6b)
C: 0.04 (EBIT TTM 796.0m / Avg Total Assets 18.8b)
D: 0.74 (Book Value of Equity 7.87b / Total Liabilities 10.7b)
Altman-Z'' = 2.91 = A
Beneish M -2.76
DSRI: 1.26 (Receivables 1.96b/1.62b, Revenue 14.1b/14.7b)
GMI: 1.11 (GM 24.69% / 22.18%)
AQI: 0.97 (AQ_t 0.33 / AQ_t-1 0.34)
SGI: 0.96 (Revenue 14.1b / 14.7b)
TATA: -0.08 (NI 121.0m - CFO 1.63b) / TA 18.6b)
Beneish M = -2.76 (Cap -4..+1) = A
What is the price of EVK shares?

As of August 15, 2026, the stock is trading at EUR 18.04 with a total of 839,368 shares traded. Over the past week, the price has changed by +0.17%, over one month by +5.68%, over three months by +7.89% and over the past year by +14.52%.

Current recommended Stop Loss: 17.50 (which is 3% or 1.4 ATR below the current price).

Is EVK a buy, sell or hold?

Evonik Industries has no consensus analysts rating.

Evonik Industries (EVK) - Fundamental Data Overview as of 12 August 2026
Market Cap USD = 9.66b (8.37b EUR * 1.1537 EUR.USD)
P/E Trailing = 69.0769
P/E Forward = 19.9203
P/S = 0.5931
P/B = 1.0661
P/EG = 6.2284
Revenue TTM = 14.1b EUR
EBIT TTM = 796.0m EUR
EBITDA TTM = 2.11b EUR
Long Term Debt = 2.59b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 748.0m EUR (from shortTermDebt, last quarter)
Debt = 5.33b EUR (from shortLongTermDebtTotal, last quarter) + Leases 865.0m
Net Debt = 4.94b EUR (calculated: Debt 5.33b - CCE 390.0m)
Enterprise Value = 13.3b EUR (8.37b + Debt 5.33b - CCE 390.0m)
Interest Coverage Ratio = 3.69 (Ebit TTM 796.0m / Interest Expense TTM 216.0m)
EV/FCF = 15.73x (Enterprise Value 13.3b / FCF TTM 846.0m)
FCF Yield = 6.36% (FCF TTM 846.0m / Enterprise Value 13.3b)
FCF Margin = 5.99% (FCF TTM 846.0m / Revenue TTM 14.1b)
Net Margin = 0.86% (Net Income TTM 121.0m / Revenue TTM 14.1b)
Gross Margin = 22.18% ((Revenue TTM 14.1b - Cost of Revenue TTM 11.0b) / Revenue TTM)
Gross Margin QoQ = 24.71% (prev 25.21%)
Tobins Q-Ratio = 0.71 (Enterprise Value 13.3b / Total Assets 18.6b)
Interest Expense / Debt = 4.05% (Interest Expense 216.0m / Debt 5.33b)
Taxrate = 30.33% (37.0m / 122.0m)
NOPAT = 554.6m (EBIT 796.0m * (1 - 30.33%))
Current Ratio = 1.50 (Total Current Assets 5.66b / Total Current Liabilities 3.78b)
Debt / Equity = 0.68 (Debt 5.33b / totalStockholderEquity, last quarter 7.87b)
Debt / EBITDA = 2.34 (Net Debt 4.94b / EBITDA 2.11b)
Debt / FCF = 5.84 (Net Debt 4.94b / FCF TTM 846.0m)
Total Stockholder Equity = 8.14b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.64% (Net Income 121.0m / Total Assets 18.6b)
RoE = 1.49% (Net Income TTM 121.0m / Total Stockholder Equity 8.14b)
RoCE = 7.42% (EBIT 796.0m / Capital Employed (Equity 8.14b + L.T.Debt 2.59b))
RoIC = 3.65% (NOPAT 554.6m / Invested Capital 15.2b)
WACC = 4.72% (E(8.37b)/V(13.7b) * Re(5.92%) + D(5.33b)/V(13.7b) * Rd(4.05%) * (1-Tc(0.30)))
Discount Rate = 5.92% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 3.36 | Cagr: 0.0%
[DCF] Terminal Value 77.97% ; FCFF base≈696.4m ; Y1≈798.3m ; Y5≈1.17b
[DCF] Fair Price = 27.34 (EV 17.7b - Net Debt 4.94b = Equity 12.7b / Shares 466.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 47.90 | EPS CAGR: 13.76% | SUE: 1.37 | # QB: 1
Revenue Correlation: -91.37 | Revenue CAGR: -4.37% | SUE: 0.06 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.45 | Chg30d=+4.71% | Revisions=+25% | Analysts=2
EPS current Year (2026-12-31): EPS=1.68 | Chg30d=+6.91% | Revisions=+44% | GrowthEPS=+23.2% | GrowthRev=+3.9%
EPS next Year (2027-12-31): EPS=1.48 | Chg30d=+0.18% | Revisions=+44% | GrowthEPS=-11.9% | GrowthRev=-1.3%
[Analyst] Revisions Ratio: +56% (up=11, down=2)